Targeting extracellular CIRP with an X-aptamer shows therapeutic potential in acute pancreatitis

Wuming Liu,Jianbin Bi,Yifan Ren,Huan Chen,Jia Zhang,Tao Wang,Mengzhou Wang,Lin Zhang,Junzhou Zhao,Zheng Wu,Yi Lv,Bing Liu,Rongqian Wu
DOI: https://doi.org/10.1016/j.isci.2023.107043
IF: 5.8
2023-07-01
iScience
Abstract:Severe acute pancreatitis (AP) is associated with a high mortality rate. Cold-inducible RNA binding protein (CIRP) can be released from cells in inflammatory conditions and extracellular CIRP acts as a damage-associated molecular pattern. This study aims to explore the role of CIRP in the pathogenesis of AP and evaluate the therapeutic potential of targeting extracellular CIRP with X-aptamers. Our results showed that serum CIRP concentrations were significantly increased in AP mice. Recombinant CIRP triggered mitochondrial injury and ER stress in pancreatic acinar cells. CIRP<sup>-/-</sup> mice suffered less severe pancreatic injury and inflammatory responses. Using a bead-based X-aptamer library, we identified an X-aptamer that specifically binds to CIRP (XA-CIRP). Structurally, XA-CIRP blocked the interaction between CIRP and TLR4. Functionally, it reduced CIRP-induced pancreatic acinar cell injury <i>in vitro</i> and L-arginine-induced pancreatic injury and inflammation <i>in vivo</i>. Thus, targeting extracellular CIRP with X-aptamers may be a promising strategy to treat AP.
multidisciplinary sciences
What problem does this paper attempt to address?